Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:58d2:0:b0:439:fcfb:30e with SMTP id o18csp95594wrf; Thu, 26 Mar 2026 15:02:51 -0700 (PDT) X-Received: by 2002:a05:620a:4726:b0:8cf:def2:c35c with SMTP id af79cd13be357-8d01c66811fmr16707085a.25.1774562571641; Thu, 26 Mar 2026 15:02:51 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774562571; cv=none; d=google.com; s=arc-20240605; b=ZgF7x5BvJ+wFsMGOBkE2vyFZuX2D7aOEaSgWBZLuObawZxxjsisNkUnbzelti7rfS5 RYoBZ4+EhIEbfHClPA3PZLJFL7d/FwaZ3UcjPgFsDLkqWtsNewBsVfoGPm8KwBVdpRFJ lIvZwCpoEwwVN6solpm6CYozbay1xOo8ZjoUss4STpgubKTFaZPbi1AybsANZKS2S13v 42PQrFmlXh4yYzPvsQJQ12fEabqOWSKvEiIdqqASbYu/9pvMVB6kT8BA2r2RBh7yeT7Z zpKM+8UeoJaOJRAz5jRgIIgP+K2Zhs/4nAQhBy05KGIdp4CCZXkM0RRHtQ9HcciunCtk h+og== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:date:mime-version:sid:subject:reply-to :list-unsubscribe-post:list-unsubscribe:from:feedback-id:to :dkim-signature:dkim-signature; bh=atOcGBPw7elUJY0DU1mCY70nwCkElSX4e8LCxMcPe3w=; fh=Hcu5VqhndQNvtVhwbc8tr7JrSOSQJms/+lG2L+E9gBs=; b=hEYdYvuW9jiEupmvcjxd+sa9pJ9IQPUo79lm/Ao0+GT+OhSpdwtC5tMBqFqGXnz7os DJGF6nggZt2bPX4myWcUFjTsHqnQ81ivNxritBBek0jYAPUCCRX/VmUKFoO7aed6T4SI CvzYGABWA8FPJhvAmh7mYMiceajzhw1oixuEYqskN2a2DG6ubBRwcZhjMa4UE3ymil9R kK8SOWhtxpx6HsszmYfxzy3b4n+8PtQAMEhJLEt8+iFdI8aK34/hnnVh4QlkRQAPpstC icO2DaAdYLxtCspVBLs7djoCQscS4Cz2iFtaRBYL9sp96BOkFGSucmV2YBQXbiVobKrh MVBg==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=hHHt+5rz; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=cR1BOidG; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.13 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com Return-Path: Received: from bh186-13.smtp-out.beehiivmail.net (bh186-13.smtp-out.beehiivmail.net. [69.67.186.13]) by mx.google.com with ESMTPS id af79cd13be357-8d00e5a6a2esi491747185a.439.2026.03.26.15.02.51 for (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256); Thu, 26 Mar 2026 15:02:51 -0700 (PDT) Received-SPF: pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.13 as permitted sender) client-ip=69.67.186.13; Authentication-Results: mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=hHHt+5rz; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=cR1BOidG; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.13 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com X-BmtaRef: eyJfQF8iOiJcXF8vIiwicmVjaXBpZW50IjoidGpwaHVoc0BnbWFpbC5jb20iLCJ4X2xpc3RfaWQiOiJmZDQxNjMwZS1lOTFmLTQ2ZDktYTI3NC1iNzQwZGFiNzU2ZDIiLCJ4X3N1YnNjcmliZXJfaWQiOiI5YzQwZDYzOS02ZTFkLTQyOTItYTlkNy0wZTRjYmJiNWQ1ZGIifQ== DKIM-Signature: v=1; a=rsa-sha256; d=bhmta.beehiiv.com; s=bh; c=relaxed/relaxed; bh=atOcGBPw7elUJY0DU1mCY70nwCkElSX4e8LCxMcPe3w=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1774562571; b=hHHt+5rzM2ZuJ6cTofL0u4oM87TaN96mWoIRuWWV6iO5W+JV+BZXEj8YA03M994pvegMhVIcG wpR0mtAiBbeDRiyPDLHqFQIWX33yM9Q3T3Hdox6+La23Qzlq0FL7KXZK5q/ALJCdkBCrPgOi+W7 d7ijhYHKVFznzvO5sbSVLFv9F865lSVBib4JkR7wRhoFXcbG33e4aAkSfpA/pjfU4MvnaSk8eeK Kmuy0f+VauueJuA5PACb35k1R1zbPURmmftp7GJXyBYmSY8D0AuOa3Yjnrc3rrTq+pyHravCMH4 EgPwJpN0fc3aDgcEG0CXJc4S/EVOUn+8BuNM+HLG2+aQ==; DKIM-Signature: v=1; a=rsa-sha256; d=mail.beehiiv.com; s=bh; c=relaxed/relaxed; bh=atOcGBPw7elUJY0DU1mCY70nwCkElSX4e8LCxMcPe3w=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1774562571; b=cR1BOidGkWrsmvu6bZ8KV53iDanN9kmYDBcpr6RuNo/8GCK1GqHa7g8dc7cuyF60tCb9COEEe 550HLQuwu7ZsL0lKgr98TJVRLJYt1d8HgeYdHDOXmaCQx7QWgqyj+16oUd9mibj+KYl872L5D0u 25LFfglFEpgadGrYSduK6F9oOYUm101rJ9fjkCG1dqMWDMNUyGq9LIVprwPl+Vm0yvDYs4kFq9O PuYSbeTJZZnrLXS4k2igOIp1XKOUdoEpaGAVbmKNo2CtRLU7dBEcv1mR77C4BX9bJ5F32CZfbKk zLpDH5CBF2UkVoC5z3IgQDhEuitc84KQca3k+jxVZp0A==; Received: from mail.beehiiv.com by bhmta(mta25) with HTTP id <888daf4f295f11f190b512d5d5ddf6df> for ; Thu, 26 Mar 2026 22:02:51 +0000 Content-Type: multipart/alternative; boundary="HUyLvXscQAKBeQW4BGnj/A" To: "tjphuhs@gmail.com" Feedback-ID: ec2f096d-b768-416b-9469-55792aa22839:newsletter:fd41630e-e91f-46d9-a274-b740dab756d2:c8f61fda6a60803 From: Hunter Williams List-Unsubscribe: , List-Unsubscribe-Post: List-Unsubscribe=One-Click Reply-To: =?utf-8?Q?Hunter=27s_Health_Hacks?= Subject: Your BPC-157 Experience Could Change FDA policy X-Batch-Id: dfe909bb-c863-425a-904b-704930d0c616 X-Subscriber-ID: 9c40d639-6e1d-4292-a9d7-0e4cbbb5d5db sId: fd41630e-e91f-46d9-a274-b740dab756d2 x-beehiiv-ids: {"account_name":"https://huntershealthhacks.beehiiv.com/","campaign_id":"ec2f096d-b768-416b-9469-55792aa22839","category":"newsletter","email_generated_at":1774562569,"user_id":"fd41630e-e91f-46d9-a274-b740dab756d2"} x-beehiiv-type: newsletter x-list-id: fd41630e-e91f-46d9-a274-b740dab756d2 x-list-owner: x-newsletter: https://huntershealthhacks.beehiiv.com/p/your-bpc-157-experience-could-change-fda-policy x-newsletter-id: https://huntershealthhacks.beehiiv.com/ x-newsletter-signup: https://huntershealthhacks.beehiiv.com/subscribe Mime-Version: 1.0 Date: Thu, 26 Mar 2026 22:02:51 +0000 Message-ID: <20260326.220251.2b0745df@mta25> --HUyLvXscQAKBeQW4BGnj/A Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Happy Thursday!=0A=0AThe FDA classified BPC-157 as a Category 2 bulk drug s= ubstance in 2023.=0A=0ATheir reasoning? Insufficient evidence on whether it= causes harm to humans.=0A=0AMeanwhile, hundreds of thousands of people hav= e used BPC-157, including many of you reading this right now. And most of y= ou walked away with zero adverse events and a healed injury.=0A=0ABut as of= now, we have no documented way to verify the safety and efficacy of some o= f the most common and effective peptides.=0A=0AWell, hopefully that=E2=80= =99s about to change.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Project**=0A=0AI'v= e been working on something behind the scenes with a team of heavy hitters = that I'm finally ready to share with you.=0A=0AIt's called the **Peptide Sa= fety Initiative**.=0A=0AThe FDA says there isn't enough human safety data o= n BPC-157 to justify allowing compounding pharmacies to produce it. The pub= lished clinical data are razor-thin. One small pilot study. A couple of ret= rospective case reviews. No large-scale human trials.=0A=0ABut what does th= e FDA not have access to?=0A=0AYour experience.=0A=0AThe real-world experie= nce of the thousands of people who have used BPC-157 for gut healing, tendo= n repair, joint recovery, post-surgical rehab, and everything in between.= =0A=0AThat gap between what regulators see on paper and what our community = has experienced firsthand is the entire problem.=0A=0ASo we built a tool to= close that gap.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Peptide Safety Initia= tive**=0A=0AWe created a structured reporting platform where you can docume= nt your personal experience with BPC-157. The data gets aggregated and de-i= dentified. Then it goes directly to the doctors and researchers working wit= h the FDA on peptide reclassification.=0A=0AThis is a real-world evidence c= ollection effort modeled after the kind of data regulatory bodies actually = take seriously.=0A=0AThere is a commission currently reviewing the Category= 2 designation for several peptides. =0A=0AThe doctors on that commission n= eed volume. =0A=0AThey need to show the FDA that real humans have used this= compound, here's what happened, and here's the safety profile across a lar= ge population.=0A=0AGood, bad, or neutral. All of it matters.=0A=0A=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=0A=0A**What You'll Be Asked**=0A=0AThe form takes a few minute= s. There are two tracks.=0A=0A**If you're a clinician or prescriber**, you'= ll document your professional experience with BPC-157 across your patient p= opulation. =0A=0AClinical indications you treated. Objective outcomes you o= bserved. Routes of administration, dosing protocols, duration of use, and s= ourcing. =0A=0AThere's a dedicated adverse event reporting section covering= injection site reactions, fluid retention, hypoglycemia symptoms, cardiac = changes, neuropsychiatric effects, GI issues, and blood pressure fluctuatio= ns. =0A=0AYou'll also rate the overall safety profile on a 0 to 10 scale ba= sed on your clinical judgment.=0A=0A**If you're an individual user**, you'l= l share basic demographics (age, sex, height, weight, ethnicity), what your= goal was for using BPC-157, what results you experienced, your dosing deta= ils, and where you sourced it. =0A=0AYou'll go through the same adverse eve= nt checklist covering injection site reactions, swelling, hypoglycemia symp= toms, heart rate changes, mood effects, GI distress, and blood pressure cha= nges. You'll rate overall safety on the same 0 to 10 scale.=0A=0ABoth track= s ask whether you discontinued use due to side effects. And both give you s= pace to share additional details like lab values, imaging findings, or reco= very stories.=0A=0AEverything is voluntary. Everything is anonymous.=0A=0A= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=0A=0A**Why This Matters **=0A=0AThe regulatory landscape= around peptides is shifting fast. There are people inside the system right= now who are willing to fight for reclassification. But they need ammunitio= n.=0A=0AAnecdotes in a Reddit thread don't move regulatory bodies, but stru= ctured, aggregated real-world evidence from hundreds or thousands of people= does.=0A=0AThink about what we're up against. =0A=0AThe FDA's position is = that there's not enough human data. That's technically true when you look a= t published clinical trials. But it completely ignores the massive real-wor= ld evidence base sitting inside this community.=0A=0AWe can change that. Bu= t only if enough people participate.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**What Ha= ppens With Your Data**=0A=0AYour submissions are aggregated into a de-ident= ified dataset. =0A=0ANo personal information gets shared with anyone. =0A= =0AThe compiled data is presented to the physicians and researchers on the = FDA advisory commission reviewing peptide classifications.=0A=0A**That's it= . No middlemen. No commercial interests. No product to sell you. Just commu= nity data going where it needs to go.**=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Fina= l Thoughts**=0A=0AThe biggest threat to peptide access is the absence of or= ganized data from the people who actually use these compounds.=0A=0AWe have= the community. We have the experience. We've just never had a system to ca= pture it in a way that regulators take seriously.=0A=0ANow we do.=0A=0AIf B= PC-157 helped you heal a torn tendon, recover from gut issues, bounce back = from surgery, or anything else, your experience is valuable evidence. Don't= let it sit in your memory. Put it on record.=0A=0A**[Submit your BPC-157 e= xperience here](https://www.peptidesafetyinitiative.com/bpc-157)**=0A=0AIf = you're a clinician who has prescribed or administered BPC-157, your data ca= rries even more weight. The form has a dedicated track for you. Please take= five minutes and fill it out.=0A=0AWe're starting with BPC-157 because it'= s the most widely used and the most immediately relevant to reclassificatio= n efforts. Other peptides will follow.=0A=0AShare this with anyone you know= who has used BPC-157. Patients, providers, training partners, anyone. The = more data points we collect, the stronger the case becomes.=0A=0AThanks for= being part of this!=0A=0ABest,=0A=0AHunter Williams =0A=0A=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=0A=0A**P.S.** If you had a negative experience with BPC-157, that data = is just as important. We are not cherry picking! Honesty is what gives this= data credibility with regulators. If we only show them the wins, they'll d= ismiss the whole thing. We need the full picture.=0A=0A=0A=E2=80=94=E2=80= =94=E2=80=94=0A=0AYou are reading a plain text version of this post. For th= e best experience, copy and paste this link in your browser to view the pos= t online:=0Ahttps://huntershealthhacks.beehiiv.com/p/your-bpc-157-experienc= e-could-change-fda-policy --HUyLvXscQAKBeQW4BGnj/A Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Your BPC-157 Experience Could Change FDA policy
Jus= t 5 minutes of your time  ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=
<= /tr><= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

The regulatory landscape around peptides is shifting= fast. There are people inside the system right now who are willing to figh= t for reclassification. But they need ammunition.

<= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

Anecdotes in a Reddit thread don't move regulato= ry bodies, but structured, aggregated real-world evidence from hundreds or = thousands of people does.

March 26, 2026   |=   Read online

Your BPC-157 Experience Co= uld Change FDA policy

Just 5 minutes of your time

3D"share
 
= 3D"share
 
3D"share
 <= td align=3D"center" valign=3D"middle" style=3D"border: 1px solid #E5E7EB; b= order-radius: 100%; width: 18px; height: 18px; padding: 8px;">3D"share
3D""
<= /tr>

Happy Thursday!

The FDA classified BPC-157 as a Category 2 b= ulk drug substance in 2023.

Their reasoning? Insufficient evidence on whether it causes harm to humans= .

Meanwhile, hundreds of tho= usands of people have used BPC-157, including many of you reading this righ= t now. And most of you walked away with zero adverse events and a healed in= jury.

But as of now, we have= no documented way to verify the safety and efficacy of some of the most co= mmon and effective peptides.

Well, hopefully that=E2=80=99s about to change.

=
 

T= he Project

I've been= working on something behind the scenes with a team of heavy hitters that I= 'm finally ready to share with you.

It's called the = Peptide Safety Initiative.<= /span>

The FDA says there isn't= enough human safety data on BPC-157 to justify allowing compounding pharma= cies to produce it. The published clinical data are razor-thin. One small p= ilot study. A couple of retrospective case reviews. No large-scale human tr= ials.

But what does the FDA = not have access to?

Your exp= erience.

The real-world expe= rience of the thousands of people who have used BPC-157 for gut healing, te= ndon repair, joint recovery, post-surgical rehab, and everything in between= .

That gap between what regu= lators see on paper and what our community has experienced firsthand is the= entire problem.

So we built= a tool to close that gap.

 

The Peptide Safety Initia= tive

We created a struct= ured reporting platform where you can document your personal experience wit= h BPC-157. The data gets aggregated and de-identified. Then it goes directl= y to the doctors and researchers working with the FDA on peptide reclassifi= cation.

This is a real-world= evidence collection effort modeled after the kind of data regulatory bodie= s actually take seriously.

There is a commission currently reviewing the Category 2 designation for s= everal peptides.

The doct= ors on that commission need volume.

They need to show the FDA that real humans have used this compound= , here's what happened, and here's the safety profile across a larg= e population.

Good, bad, or = neutral. All of it matters.

 

What You'll Be Asked=

The form takes a few mi= nutes. There are two tracks.

If you're a clinician or prescriber, you'll document your professional experience with BPC-15= 7 across your patient population.

Clinical indications you treated. Objective outcomes you observed. R= outes of administration, dosing protocols, duration of use, and sourcing. <= /span>

There's a dedicated adve= rse event reporting section covering injection site reactions, fluid retent= ion, hypoglycemia symptoms, cardiac changes, neuropsychiatric effects, GI i= ssues, and blood pressure fluctuations.

You'll also rate the overall safety profile on a 0 to 10 = scale based on your clinical judgment.

If you're an individual user, you'll share basic demographics (age, sex, height, we= ight, ethnicity), what your goal was for using BPC-157, what results you ex= perienced, your dosing details, and where you sourced it.

You'll go through the same adverse event= checklist covering injection site reactions, swelling, hypoglycemia sympto= ms, heart rate changes, mood effects, GI distress, and blood pressure chang= es. You'll rate overall safety on the same 0 to 10 scale.

= Both tracks ask whether you discontinued = use due to side effects. And both give you space to share additional detail= s like lab values, imaging findings, or recovery stories.

Everything is voluntary. Everything is anonym= ous.

 

Why This Matters

Th= ink about what we're up against.

The FDA's position is that there's not enough human data.= That's technically true when you look at published clinical trials. Bu= t it completely ignores the massive real-world evidence base sitting inside= this community.

We can chan= ge that. But only if enough people participate.

 

What= Happens With Your Data

Your submissions are aggregated into a de-identified dataset.

<= /td>

No personal information gets shared wit= h anyone.

The compiled data= is presented to the physicians and researchers on the FDA advisory commiss= ion reviewing peptide classifications.

That's it. No middlemen. No commercial interests. No prod= uct to sell you. Just community data going where it needs to go.=

 

Final Thoughts

The biggest threat to peptide access is the absence of organized da= ta from the people who actually use these compounds.

We have the community. We have the experience. We&= #39;ve just never had a system to capture it in a way that regulators take = seriously.

Now we do.=

If BPC-157 helped you heal a torn = tendon, recover from gut issues, bounce back from surgery, or anything else= , your experience is valuable evidence. Don't let it sit in your memory= . Put it on record.

Submit your BPC-157 experience here

If you're a clinician who h= as prescribed or administered BPC-157, your data carries even more weight. = The form has a dedicated track for you. Please take five minutes and fill i= t out.

We're starting wi= th BPC-157 because it's the most widely used and the most immediately r= elevant to reclassification efforts. Other peptides will follow.

=

Share this with anyone you know who ha= s used BPC-157. Patients, providers, training partners, anyone. The more da= ta points we collect, the stronger the case becomes.

Thanks for being part of this!

Best,

Hunter Williams

<= /table>=
 

P.S. If you had a negative experience with BPC-157, that= data is just as important. We are not cherry picking! Honesty is what give= s this data credibility with regulators. If we only show them the wins, the= y'll dismiss the whole thing. We need the full picture.

<= /tr><= tr>
3D"ig"3D"y=<= span style=3D"padding-left:1px;">

Want more?= Here=E2=80=99s how you can work with me:

=F0=9F=91=89Join my private co= aching group, The AXION Collective:

=F0=9F=91=89= Try Zeroats, the world=E2=80=99s first sugar-free, naturally flavored oatme= al:

=F0=9F=91=89Get the Peptide Cheat Sheet:
=F0=9F=91=89All my daily essentials on Amazo= n
=

= =F0=9F=91=89Get discounts on your favorit= e peptides and research chemicals:

=F0=9F=91=8910% off the BEST workout supplem= ents from Unmatched Supps (pre-workout, whey protein, creatine, EAAs, elect= rolytes - use code HUNTERW at checkout):

=F0=9F=91=89Submit A Video Topic For M= y Next YouTube Video:

<= div style=3D"margin-left:0px;" class=3D"edm_outlooklist">

Update your email preferences = or unsubscribe here

© 2026 Hunter's H= ealth Hacks

228 Park Ave S, #29976, New York, New York 10003, Unite= d States

3D"beeh= Te= rms of Service
--HUyLvXscQAKBeQW4BGnj/A--